Shanxi Ante Bio-Pharmaceutical Co., Ltd.

Primary study objective: To evaluate the clinical efficacy equivalence of 5% minoxidil foam and ROGAINE® (5% minoxidil foam) in adult male subjects with androgenetic alopecia (AGA). Secondary study objective: To compare the safety of the test drug and the control drug in adult male subjects with androgenetic alopecia.

In healthy subjects, the pharmacokinetics of trimebutine maleate tablets (specification: 100 mg; test preparation) developed by Shanxi Zhendong Anxin Biopharmaceutical Co., Ltd. were studied under fasting and postprandial conditions, using trimebutine maleate tablets (trade name: Cerekinon®; specification: 100 mg) owned by Mitsubishi Tanabe Pharma Corporation as the reference preparation, and the bioequivalence of the test preparation and the reference preparation was evaluated. Secondary study objective: To observe the safety of oral administration of the test preparation and the reference preparation in healthy subjects.

The efficacy and safety of quadruple therapy containing colloidal bismuth pectin capsules in eradicating Hp were evaluated by using quadruple therapy containing potassium citrate bismuth tablets as a control.